Title
Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
Document Type
Article
Publication Date
1-2-2017
Abstract
Background—Persistent immune activation and inflammation in virologically suppressed HIV infection are linked to excess cardiovascular risk. Objective—To evaluate atorvastatin as a strategy to reduce cardiovascular risk. Methods—A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-over pilot study of atorvastatin (10mg/day for 4 weeks then 20mg/day for 16 weeks) with a planned enrollment of 97 HIV-infected participants ≥18 years old, receiving boosted protease inhibitor-based ART for ≥6 months, with plasma HIV-1 RNAs below limits of quantification ≥180 days, and fasting LDL-C ≥70 mg/dL and
Digital Commons Citation
Nixon, D E.; Bosch, R J.; Chan, E S.; and Funderburg, N T., "Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg>/dL (AIDS Clinical Trials Group Study A5275)." (2017). Clinical and Translational Science Institute. 553.
https://researchrepository.wvu.edu/ctsi/553